Format
Items per page
Sort by

Send to:

Choose Destination

Results: 15

Related Articles by Review for PubMed (Select 21980429)

1.

Inhibition of glycogen synthase kinase-3β counteracts ligand-independent activity of the androgen receptor in castration resistant prostate cancer.

Schütz SV, Schrader AJ, Zengerling F, Genze F, Cronauer MV, Schrader M.

PLoS One. 2011;6(9):e25341. doi: 10.1371/journal.pone.0025341. Epub 2011 Sep 29.

2.

Experimental evidence of persistent androgen-receptor-dependency in castration-resistant prostate cancer.

Kobayashi T, Inoue T, Kamba T, Ogawa O.

Int J Mol Sci. 2013 Jul 26;14(8):15615-35. doi: 10.3390/ijms140815615. Review.

3.

Multifaceted interaction between the androgen and Wnt signaling pathways and the implication for prostate cancer.

Terry S, Yang X, Chen MW, Vacherot F, Buttyan R.

J Cell Biochem. 2006 Oct 1;99(2):402-10. Review.

PMID:
16741972
4.

Oncogenic activation of androgen receptor.

Kung HJ, Evans CP.

Urol Oncol. 2009 Jan-Feb;27(1):48-52. doi: 10.1016/j.urolonc.2008.06.002. Review.

5.

Molecular biology of castration-resistant prostate cancer: basis for the novel therapeutic targets.

Mellado B, Marin Aguilera M, Pereira MV.

Arch Esp Urol. 2013 Jun;66(5):453-62. Review.

PMID:
23793763
6.

Interplay between genomic alterations and androgen receptor signaling during prostate cancer development and progression.

Nyquist MD, Dehm SM.

Horm Cancer. 2013 Apr;4(2):61-9. doi: 10.1007/s12672-013-0131-4. Epub 2013 Jan 10. Review.

7.

Androgen receptor gene rearrangements: new perspectives on prostate cancer progression.

Brand LJ, Dehm SM.

Curr Drug Targets. 2013 Apr;14(4):441-9. Review.

8.

Posttranslational modification of the androgen receptor in prostate cancer.

van der Steen T, Tindall DJ, Huang H.

Int J Mol Sci. 2013 Jul 16;14(7):14833-59. doi: 10.3390/ijms140714833. Review.

9.

Small molecule inhibitors targeting the "achilles' heel" of androgen receptor activity.

Sadar MD.

Cancer Res. 2011 Feb 15;71(4):1208-13. doi: 10.1158/0008-5472.CAN_10-3398. Epub 2011 Feb 1. Review.

10.

GSK-3 inhibitors and insulin receptor signaling in health, disease, and therapeutics.

Wada A.

Front Biosci (Landmark Ed). 2009 Jan 1;14:1558-70. Review.

PMID:
19273146
11.

Specific involvement of glycogen synthase kinase-3 in the function and activity of sex steroid hormone receptors reveals the complexity of their regulation.

Grisouard J, Mayer D.

J Steroid Biochem Mol Biol. 2009 Nov;117(4-5):87-92. doi: 10.1016/j.jsbmb.2009.08.002. Epub 2009 Aug 22. Review.

PMID:
19703560
12.

Targeting GSK-3: a promising approach for cancer therapy?

Ougolkov AV, Billadeau DD.

Future Oncol. 2006 Feb;2(1):91-100. Review.

PMID:
16556076
13.

Glycogen synthase kinase-3β (GSK-3β) and its dysregulation in glioblastoma multiforme.

Atkins RJ, Stylli SS, Luwor RB, Kaye AH, Hovens CM.

J Clin Neurosci. 2013 Sep;20(9):1185-92. doi: 10.1016/j.jocn.2013.02.003. Epub 2013 Jun 12. Review.

PMID:
23768967
14.

GSK-3 inhibition: achieving moderate efficacy with high selectivity.

Avrahami L, Licht-Murava A, Eisenstein M, Eldar-Finkelman H.

Biochim Biophys Acta. 2013 Jul;1834(7):1410-4. doi: 10.1016/j.bbapap.2013.01.016. Epub 2013 Jan 29. Review.

PMID:
23369789
15.

Diverse roles of GSK-3: tumor promoter-tumor suppressor, target in cancer therapy.

McCubrey JA, Davis NM, Abrams SL, Montalto G, Cervello M, Basecke J, Libra M, Nicoletti F, Cocco L, Martelli AM, Steelman LS.

Adv Biol Regul. 2014 Jan;54:176-96. doi: 10.1016/j.jbior.2013.09.013. Epub 2013 Oct 8. Review. No abstract available.

PMID:
24169510
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk